The rapidly evolving treatment landscape in prostate cancer brings both opportunities and challenges. The availability of new therapies for nmCRPC presents healthcare professionals with a wealth of options, and advances in the mHSPC setting raise questions on how to treat these patients as they progress to mCRPC – how can we ensure that the evolution in treatment landscape leads to improved outcomes for patients with CRPC?

Using a case-based approach, P3 provides a forum for attendees to review the clinical evidence and discuss the management of advanced prostate cancer with experts and fellow healthcare professionals.


Michael Gorin, MD

Milton and Carroll Petrie Department of Urology
Icahn School of Medicine
Mount Sinai, New York
View Full Bio


In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and Remedica Medical Education and Publishing, Ltd.. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This live activity is designated for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.


UK Healthcare CECentral certifies this activity for 1.50 hours of participation.


This activity is jointly provided by the University of Kentucky and Remedica Medical Education and Publishing, Ltd.

Supported by an unrestricted educational grant from Bayer.